Cubist surges on positive PhIII antibiotic study

Shares of Cubist Pharmaceuticals ($CBST) surged this morning after the Lexington, MA-based company announced that it had reaped promising data from its Phase III of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections. Ceftolozane/tazobactam met its primary endpoint of statistical noninferiority compared to levofloxacin. And the adverse event rate appeared almost identical in both arms of the study. Another Phase III study for complicated intra-abdominal infections is underway and due to read out next month, offering the final piece of a Phase III puzzle that Cubist plans to take to the FDA in search of an approval. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.